Assembly Biosciences Doses First Participant In Phase 1B Portion Of Phase 1A/B Clinical Trial Of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor Abi-1179
Assembly Biosciences Inc ASMB.O:
ASSEMBLY BIOSCIENCES DOSES FIRST PARTICIPANT IN PHASE 1B PORTION OF PHASE 1A/B CLINICAL TRIAL OF INVESTIGATIONAL LONG-ACTING HERPES SIMPLEX VIRUS HELICASE-PRIMASE INHIBITOR ABI-1179
ASSEMBLY BIOSCIENCES INC - INTERIM DATA FOR ABI-5366 AND ABI-1179 EXPECTED IN FALL 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.